Head and neck mucosal melanoma: A review

American Journal of Dermatopathology

Volumn 36, Issue 7, 2014, Pages 578-587

  Lourenço, Silvia V ^a   Fernandes, Juliana D ^b   Hsieh, Ricardo ^a   Coutinho Camillo, Claudia M ^c   Bologna, Sheyla ^a   Sangueza, Martin ^d   Nico, Marcello M S ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^c A C CAMARGO CANCER CENTER   (Brazil)

^d Hospital Obrero   (Bolivia)

Author keywords

head and neck; melanoma; mucosal

Indexed keywords

MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P16; PROTEIN TYROSINE KINASE;

CANCER EPIDEMIOLOGY; CANCER GENETICS; CANCER STAGING; CANCER SURVIVAL; CUTANEOUS MELANOMA; ENZYME ACTIVATION; ESOPHAGUS; HEAD AND NECK CANCER; HEAD AND NECK MUCOSAL MELANOMA; HISTOPATHOLOGY; HUMAN; LARYNX MELANOMA; LARYNX TUMOR; MELANOCYTE; MELANOGENESIS; MOLECULAR PATHOLOGY; MOUTH CAVITY; MOUTH TUMOR; NONHUMAN; NOSE CAVITY; PHARYNX MELANOMA; PHARYNX TUMOR; PRIMARY TUMOR; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SKIN CARCINOGENESIS; SURVIVAL RATE; HEAD AND NECK NEOPLASMS; MELANOMA; MUCOSA; PATHOLOGY;

HEAD AND NECK NEOPLASMS; HUMANS; MELANOMA; MUCOUS MEMBRANE;

EID: 84903303828     PISSN: 01931091     EISSN: 15330311     Source Type: Journal    
DOI: 10.1097/DAD.0000000000000035     Document Type: Review

References (89)

1. Nandapalan V, Roland NJ, Helliwell TR, et al. Mucosal melanoma of the head and neck. Clin Otolaryngol Alled Sci. 1998;23: 107-116.
2. Weber CO. Surgical Experience and Research, in Addition to Interesting Observations from the Surgical Clinic and the Protestant Hospital Bonn. Berlin, Germany: G. Reimer; 1859: 304-305.
3. McLaughlin CC, Wu XC, Jemal A, et al. Incidence of noncutaneous melanomas in the US. Cancer. 2005;103: 1000-1007.
4. Manolidis S, Donald PJ. Malignant mucosal melanoma of the head and neck: review of the literature and report of 14 patients. Cancer. 1997;80: 1373-1386.
5. Lourenço SV, Sangueza M, Sotto MN, et al. Primary oral mucosal melanoma: a series of 35 new cases from South America. Am J Dermatopathol. 2009;31: 323-330.
6. Anderson LJ, Berthelsen A, Hansen HS. Malignant melanoma of the upper respiratory tract and the oral cavity. J Otolaryngol. 1992;21: 180-185.
7. Ross MI, Henderson MA. Mucosal melanoma. In: Balch CM, Houghton AN, Sober AJ, et al, eds. Cutaneous Melanoma. 5th ed. St Louis, MO: Quality Medical Publishing; 2009: 337-350.
8. Thompson LD, Wieneke JA, Miettinen M. Sinonasal tract and nasopharyngeal melanomas: a clinicopathologic study of 115 cases with a proposed staging system. Am J Surg Pathol. 2003;27: 594-611.
9. Patel SG, Prasad ML, Escrig M. Primary mucosal malignant melanoma of the head and neck. Head Neck. 2002;24: 247-257.
10. Owens JM, Roberts DB, Myers JN. The role of postoperative adjuvant radiation therapy in the treatment of mucosal melanomas of the head and neck region. Arch Otolaryngol Head Neck Surg. 2003;129: 864-868.
11. Barrett AW, Raja AM. The immunohistochemical identification of human oral mucosal melanocytes. Arch Oral Biol. 1997;42: 77-81.
12. Mackintosh JA. The antimicrobial properties of melanocytes, melanosomes and melanin and the evolution of black skin. J Theor Biol. 2001;211: 101-113.
13. Plonka PM, Passeron T, Brenner M, et al. What are melanocytes really doing all day long...? Exp Dermatol. 2009;18: 799-819.
14. Trap TK, Fu Y, Calcaterra TC. Melanoma of the nasal and paranasal sinus mucosa. Arch Otolaryngol Head Neck Surg. 1987;113: 1086-1089.
15. Papaspyrou G, Garbe C, Schadendorf D, et al. Mucosal melanomas of the head and neck: new aspects of the clinical outcome, molecular pathology, and treatment with c-kit inhibitors. Melanoma Res. 2011;21: 475-482.
16. Gorsky M, Epstein JB. Melanoma arising from the mucosal surfaces of the head and neck. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998;86: 715-719.
17. Kaufman HL, Kirkwood JM, Hodi FS, et al. The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol. 2013;10: 588-598.
18. Patrick RJ, Fenske NA, Messina JL. Primary mucosal melanoma. J Am Acad Dermatol. 2007;56: 828-834.
19. Chang AE, Karnell LH, Mench HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84836 cases from the past decade. Cancer. 1998;83: 1664-1678.
20. Wong CW, Fan YS, Chan TL, et al. BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs. J Clin Pathol. 2005;58: 640-644.
21. Takagi M, Ishikawa G, Mori W. Primary malignant melanoma of the oral cavity in Japan, with special reference to mucosal melanosis. Cancer. 1974;34: 358-370.
22. Cheng YF, Lai CC, Ho CY, et al. Toward a better understanding of sinonasal mucosal melanoma: clinical review of 23 cases. J Chin Med Assoc. 2007;70: 24-29.
23. Batsakis JG, Regezi JA, Solomen AR, et al. The pathology of head and neck tumors: mucosal melanomas. Head Neck Surg. 1982;4: 404-418.
24. Liversedge RL. Oral malignant melanoma. Br J Oral Surg. 1975;13: 40-55.
25. Kanetaka S, Tsukuda M, Takahashi M, et al. Mucosal melanoma of the head and neck. Exp Ther Med. 2011;2: 907-910.
26. Stern SJ, Guillamondegui OM. Mucosal melanoma of the head and neck. Head Neck. 1991;27: 13-22.
27. Gilligan D, Slevin NJ. Radical radiotherapy for 28 cases of mucosal melanoma in the nasal cavity and sinuses. Br J Radiol. 1991;64: 1147-1150.
28. Shibuya H, Takeda M, Matsumoto S, et al. The efficacy of radiation therapy for a malignant melanoma in the mucosa of the upper jaw: an analytic study. Int J Radiat Oncol Biol Phys. 1992;25: 35-39.
29. Krengli M, Masini L, Kaanders JH, et al. Radiotherapy in the treatment of mucosal melanoma of the upper aerodigestive tract: analysis of 74 cases. A Rare Cancer Network study. Int J Radiat Oncol Biol Phys. 2006; 65: 751-759.
30. Berthelsen A, Andersen AP, Jensen S, et al. Melanomas of the mucosa in the oral cavity and upper respiratory passages. Cancer. 1984;54: 907-912.
31. Guzzo M, Grandi C, Licitra L, et al. Mucosal malignant melanoma of head and neck: forty-eight cases treated at Istituto Nazionale Tumori of Milan. Eur J Surg Oncol. 1993;19: 316-319.
32. Nakashima JP, Viegas CM, Fassizoli AL, et al. Postoperative adjuvant radiation therapy in the treatment of primary head and neck mucosal melanomas. ORL J Otorhinolaryngol Relat Spec. 2008;70: 344-351.
33. Rapini RP, Golitz LE, Greer RO, et al. Primary malignant melanoma of the oral cavity: a review of 177 cases. Cancer. 1985;55: 1543-1551.
34. Prasad ML, Patel SG, Huvos AG, et al. Primary mucosal melanoma of the head and neck: a proposal for microstaging localized, stage I (lymph node-negative) tumors. Cancer. 2004;100: 1657-1664.
35. Mendenhall WM, Amdur RJ, Hinerman RW, et al. Head and neck mucosal melanoma. Am J Clin Oncol. 2005;28: 626-630.
36. Medhi P, Biswas M, Das D, et al. Cytodiagnosis of mucosal malignant melanoma of nasal cavity: a case report with review of literature. J Cytol. 2012;29: 208-210.
37. Ravid JM, Esteves JA. Malignant melanoma of the nose and paranasal sinuses and juvenile melanoma of the nose. Arch Otolaryngol. 1960;72: 431-444.
38. McLean N, Tighiouart M, Muller S. Primary mucosal melanoma of the head and neck. Comparison of clinical presentation and histopathologic features of oral and sinonasal melanoma. Oral Oncol. 2008;44: 1039-1046.
39. Prasad ML, Busam KJ, Patel SG, et al. Clinicopathologic differences in malignant melanoma arising in oral squamous and sinonasal respiratory mucosa of the upper aerodigestive tract. Arch Pathol Lab Med. 2003;127: 997-1002.
40. Van Dijk M, Sprenger S, Rombout P, et al. Distinct chromosomal aberrations in sinonasal mucosal melanoma as detected by comparative genomic hybridization. Genes Chromsomes Cancer. 2003;36: 151-158.
41. Aguas SC, Quarracino MC, Lence AN, et al. Primary melanoma of the oral cavity: ten cases and review of 177 cases from literature. Med Oral Patol Oral Cir Bucal. 2009;14:E265-E271.
42. Femiano F, Lanza A, Buonaiuto C, et al. Oral malignant melanoma: a review of the literature. J Oral Pathol Med. 2008;37: 383-388.
43. Sortino-Rachou AM, Cancela M, Voti L, et al. Primary oral melanoma: population-based incidence. Oral Oncol. 2009;45: 254-258.
44. Garzino-Demo P, Fasolis M, Maggiore GM, et al. Oral mucosal melanoma: a series of case reports. J Craniomaxillofac Surg. 2004;32: 251-257.
45. Hicks MJ, Flaitz CM. Oral mucosal melanoma: epidemiology and pathobiology. Oral Oncol. 2000;36: 152-169.
46. Moreira RN, Santos CR, Lima NL, et al. Oral and cutaneous melanoma: similarities and differences. J Clin Med Res. 2010;2: 155-158.
47. Guevara-Canales JO, Gutiérrez-Morales MM, Sacsaquispe-Contreras SJ, et al. Malignant melanoma of the oral cavity. Review of the literature and experience in a Peruvian population. Med Oral Patol Oral Cir Bucal. 2012;17:e206-e211.
48. Arabi Mianroodi A, Mirshekari T, Taheri A. Malignant melanoma metastatic to the larynx: a case report. Ear Nose Throat J. 2013;92: E8-E9.
49. Terada T, Saeki N, Toh K, et al. Primary malignant melanoma of the larynx: a case report and literature review. Auris Nasus Larynx. 2007;34: 105-110.
50. Reuter VE, Woodruff JM. Melanoma of the larynx. Laryngoscope. 1986; 94: 389-393.
51. Buchholz W. Melanoblastomas in the region of the upper respiratory & gastrointestinal tracts [in German]. Z Laryngol Rhinol Otol. 1958;37: 549-554.
52. Moore E, Martin H. Melanoma of the upper respiratory tract. Cancer. 1955;8: 1167-1176.
53. Kim H, Park C. Primary malignant laryngeal melanoma. Yonsei Med J. 1982;23: 118-122.
54. Wenig BM. Laryngeal mucosal malignant melanoma. A clinicopathologic, immunohistochemical, and ultrastructural study of four patients and review of the literature. Cancer. 1995;75: 1568-1577.
55. Palmieri G, Capone M, Ascierto ML, et al. Main roads to melanoma. J Transl Med. 2009;14:86.
56. Hsieh R, Nico MM, Coutinho-Camillo CM, et al. The CDKN2A and MAP kinase pathways: molecular roads to primary oral mucosal melanoma. Am J Dermatopathol. 2013;35: 167-175.
57. Chin L, Garraway LA, Fisher DE. Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev. 2006;20: 2149-2182.
58. Curtin JA, Busam K, Pinkel D, et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 2006;24: 4340-4346.
59. Satzger I, Schaefer T, Kuettler U, et al. Analysis of c-KIT expression and KIT gene mutation in human mucosal melanomas. Br J Cancer. 2008;99: 2065-2069.
60. Omholt K, Grafström E, Kanter-Lewensohn L, et al. KIT pathway alterations in mucosal melanomas of the vulva and other sites. Clin Cancer Res. 2011;17: 3933-3942.
61. Turri-Zanoni M, Medicina D, Lombardi D, et al. Sinonasal mucosal melanoma: molecular profile and therapeutic implications from a series of 32 cases. Head Neck. 2013;35: 1066-1077.
62. Schoenewolf NL, Bull C, Belloni B, et al. Sinonasal, genital and acrolentiginous melanomas show distinct characteristics of KIT expression and mutations. Eur J Cancer. 2012;48: 1842-1852.
63. Rivera RS, Nagatsuka H, Gunduz M, et al. C-kit protein expression correlated with activating mutations in KIT gene in oral mucosal melanoma. Virchows Arch. 2008;452: 27-32.
64. Vance KW, Goding CR. C-kit protein expression correlated with activating mutations in KIT gene in oral mucosal melanoma. Pigment Cell Res. 2004;17: 318-325.
65. Phung B, Sun J, Schepsky A, et al. C-KIT signaling depends on microphthalmia- associated transcription factor for effects on cell proliferation. PLoS One. 2011;6:e24064.
66. Flaherty KT, Hodi FS, Fisher DE. From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer. 2012;12: 349-361.
67. Morris LG, Wen YH, Nonaka D, et al. PNL2 melanocytic marker in immunohistochemical evaluation of primary mucosal melanoma of the head and neck. Head Neck. 2008;30: 771-775.
68. Prasad ML, Jungbluth AA, Iversen K, et al. Expression of melanocytic differentiation markers in malignant melanomas of the oral and sinonasal mucosa. Am J Surg Pathol. 2001;25: 782-787.
69. Jarell AD, Lawrence D, Tsao H. The RAS/mitogen activated protein (MAP) kinase pathway in melanoma biology and therapeutics. Biologics. 2007;1: 407-414.
70. Dahl C, Guldberg P. The genome and epigenome of malignant melanoma. APMIS. 2007;115: 1161-1176.
71. Jovanovic B, Kröckel D, Linden D, et al. Lack of cytoplasmic ERK activation is an independent adverse prognostic factor in primary cutaneous melanoma. J Invest Dermatol. 2008;128: 2696-2704.
72. Venesio T, Chiorino G, Balsamo A, et al. In melanocytic lesions the fraction of BRAF V600E alleles is associated with sun exposure but unrelated to ERK phosphorylation. Mod Pathol. 2008;21: 716-726.
73. Richmond-Sinclair NM, Lee E, Cummings MC, et al. Histologic and epidemiologic correlates of P-MAPK, Brn-2, pRb, p53, and p16 immunostaining in cutaneous melanomas. Melanoma Res. 2008;18: 336-345.
74. Ghosh P, Chin L. Genetics and genomics of melanoma. Expert Rev Dermatol. 2009;4:131.
75. Maldonado JL, Fridlyand J, Patel H, et al. Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst. 2003;95: 1878-1890.
76. Buery RR, Siar CH, Katase N, et al. NRAS and BRAF mutation frequency in primary oral mucosal melanoma. Oncol Rep. 2011;26: 783-787.
77. Cohen Y, Rosenbaum E, Begum S, et al. Exon 15 BRAF mutations are uncommon in melanomas arising in nonsun-exposed sites. Clin Cancer Res. 2004;10: 3444-3447.
78. Houben R, Vetter-Kauczok CS, Ortmann S, et al. Phospho-ERK staining is a poor indicator of the mutational status of BRAF and NRAS in human melanoma. J Invest Dermatol. 2008;128: 2003-2012.
79. Edlundh-Rose E, Egyházi S, Omholt K, et al. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Res. 2006;16: 471-478.
80. van 't Veer LJ, Burgering BM, Versteeg R, et al. N-ras mutations in human cutaneous melanoma from sun-exposed body sites. Mol Cell Biol. 1989;9: 3114-3116.
81. Jang S, Atkins MB. Which drug, and when, for patients with BRAFmutant melanoma? Lancet Oncol. 2013;14:e60-e69.
82. Carlson JA, Ross JS, Slominski A, et al. Molecular diagnostics in melanoma. J Am Acad Dermatol. 2005;52: 743-775.
83. Suzuki N, Onda T, Yamamoto N, et al. Mutation of the p16/CDKN2 gene and loss of heterozygosity in malignant mucosal melanoma and adenoid cystic carcinoma of the head and neck. Int J Oncol. 2007;31: 1061-1067.
84. Tanaka N, Odajima T, Mimura M, et al. Expression of Rb, pRb2/p130, p53, and p16 proteins in malignant melanoma of oral mucosa. Oral Oncol. 2001;37: 308-314.
85. Baldovini C, Tosi AL, Di Oto E, et al. Genetic markers of oral malignant melanoma analysed by fluorescence in situ hybridisation (FISH). Virchows Arch. 2011;459: 167-173.
86. Hillbertz NS, Hirsch JM, Jalouli J, et al. Viral and molecular aspects of oral cancer. Anticancer Res. 2012;32: 4201-4212.
87. Nuñez-Troconis J, Delgado M, González G, et al. Melanosis of the vagina and human papillomavirus infection, an uncommon pathology: case report. Invest Clin. 2011;52: 269-273.
88. Dahlgren L, Schedvins K, Kanter-Lewensohn L, et al. Human papilloma virus (HPV) is rarely detected in malignant melanomas of sun sheltered mucosal membranes. Acta Oncol. 2005;44: 694-699.
89. Aguissa-Tourré AH, Li G. Genetic alterations of PTEN in human melanoma. Cell Mol Life Sci. 2012;69: 1475-1491.